Plasma concentration of isoniazid and rifampin in new tuberculosis patients with and without diabetes mellitus Source: International Congress 2015 – Treatment of TB (MDR-TB): co-morbidities, adverse effects and outcomes Year: 2015
Suboptimal moxifloxacin and levofloxacin drug exposure during treatment of patients with multidrug-resistant tuberculosis: results from a prospective study in China Source: Eur Respir J, 57 (3) 2003463; 10.1183/13993003.03463-2020 Year: 2021
Clarithromycin increases linezolid exposure in multidrug-resistant tuberculosis patients Source: Eur Respir J 2013; 42: 1614-1621 Year: 2013
Influence of diabetes mellitus on sputum conversion rate in pulmonary tuberculosis and on antituberculous drug resistance Source: International Congress 2019 – Tuberculosis and comorbidities Year: 2019
Dosage of isoniazid and rifampicin poorly predicts drug exposure in tuberculosis patients Source: Eur Respir J 2016; 48: 1237-1239 Year: 2016
Isoniazid resistance is associated with delayed culture conversion during anti-tuberculosis treatment among patients with pulmonary tuberculosis Source: International Congress 2018 – Drug-resistant tuberculosis Year: 2018
The evaluation of tuberculosis risk in diabetes mellitus patients in a high incidence of tuberculosis region Source: Annual Congress 2010 - Tuberculosis: metabolic insights Year: 2010
Effect of diabetes mellitus on the Time of mycobacterial clearance from sputum during the treatment of multi-drugs resistant tuberculosis Source: International Congress 2014 – Mycobacterium tuberculosis infection and disease: clinical epidemiology 2 Year: 2014
Shortened multidrug-resistant tuberculosis treatment in settings with a high prevalence of ofloxacin resistance Source: Eur Respir J, 50 (1) 1700598; 10.1183/13993003.00598-2017 Year: 2017
Moxifloxacin, as an alternative in the treatment of patients with the newly diagnosed pulmonary TB with monoresistance to pirazinamid, or its intolerance Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021
Side effects of isoniazid and streptomycine in patients with pulmonary tuberculosis accompanying diabetes mellitus and diabetic foot syndrome Source: Annual Congress 2008 - Clinical epidemiology of tuberculosis III Year: 2008
Prevalence of rifampicin resistance by CB-NAAT in previously treated pulmonary tuberculosis cases Source: International Congress 2016 – Update on drug-resistant tuberculosis Year: 2016
Prevalence of erythromycin resistance in lower airway bacterial isolates from patients with stable COPD Source: Eur Respir J 2005; 26: Suppl. 49, 251s Year: 2005
Treatment effectiveness among patients with newly detected pulmonary tuberculosis with diabetes mellitus comorbidity Source: Eur Respir J 2004; 24: Suppl. 48, 653s Year: 2004
Treatment with isoniazid or rifampin for latent tuberculosis infection: population-based study of hepatotoxicity, completion and costs Source: Eur Respir J, 55 (3) 1902048; 10.1183/13993003.02048-2019 Year: 2020
In vitro susceptibility to rifampin and ethambutol and treatment outcome in MAC lung disease Source: International Congress 2018 – The global impact of bronchiectasis and nontuberculous mycobacteria (NTM) Year: 2018
Long-term mortality assessment of multidrug-resistant tuberculosis patients treated with delamanid Source: Eur Respir J 2015; 45: 1498-1501 Year: 2015
Treatment results in patients with drug resistant pulmonary tuberculosis Source: Eur Respir J 2002; 20: Suppl. 38, 612s Year: 2002
Six months azithromycin treatment in COPD patients with high risk of further exacerbations Source: International Congress 2017 – Management of COPD Year: 2017
Increasing incidence of fluoroquinolone resistant tuberculosis in Bombay Source: Annual Congress 2005 - Resistant and multidrug resistant tuberculosis Year: 2005